Clal Biotechnology Industries Ltd. (CBI.TA)
ILA 35.6
(-0.84%)
ILA 35.6
(-0.84%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 104 Thousand ILS | -71.89% |
| 2022 | 370 Thousand ILS | -99.52% |
| 2021 | 76.96 Million ILS | 3.24% |
| 2020 | 74.54 Million ILS | -34.2% |
| 2019 | 113.29 Million ILS | 787.39% |
| 2018 | 12.76 Million ILS | -70.62% |
| 2017 | 43.46 Million ILS | 79.72% |
| 2016 | 24.18 Million ILS | -4.86% |
| 2015 | 25.41 Million ILS | 6.35% |
| 2014 | 23.89 Million ILS | 592.32% |
| 2013 | 3.45 Million ILS | -55.0% |
| 2012 | 7.67 Million ILS | -15.4% |
| 2011 | 9.06 Million ILS | 155.77% |
| 2010 | 3.54 Million ILS | -25.29% |
| 2009 | 4.74 Million ILS | 49.12% |
| 2008 | 3.18 Million ILS | 137.64% |
| 2007 | 1.33 Million ILS | -35.06% |
| 2006 | 2.06 Million ILS | 46.87% |
| 2005 | 1.4 Million ILS | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q1 | 36 Thousand ILS | -28.0% |
| 2023 Q4 | 16 Thousand ILS | 0.0% |
| 2023 Q2 | 36 Thousand ILS | 0.0% |
| 2023 Q3 | 16 Thousand ILS | -55.56% |
| 2023 FY | 104 Thousand ILS | -71.89% |
| 2022 Q2 | 15.62 Million ILS | 10.41% |
| 2022 Q3 | 239 Thousand ILS | -98.47% |
| 2022 FY | 370 Thousand ILS | -99.52% |
| 2022 Q4 | 50 Thousand ILS | -79.08% |
| 2022 Q1 | 14.15 Million ILS | -18.22% |
| 2021 Q2 | 19.43 Million ILS | -0.53% |
| 2021 FY | 76.96 Million ILS | 3.24% |
| 2021 Q4 | 17.3 Million ILS | -16.33% |
| 2021 Q3 | 20.68 Million ILS | 6.45% |
| 2021 Q1 | 19.53 Million ILS | -9.98% |
| 2020 Q4 | 21.7 Million ILS | -5.2% |
| 2020 FY | 74.54 Million ILS | -34.2% |
| 2020 Q1 | 15.83 Million ILS | -16.68% |
| 2020 Q2 | 14.11 Million ILS | -10.89% |
| 2020 Q3 | 22.89 Million ILS | 62.21% |
| 2019 Q4 | 19 Million ILS | 4.73% |
| 2019 Q2 | 74.37 Million ILS | 4128.48% |
| 2019 FY | 113.29 Million ILS | 787.39% |
| 2019 Q1 | 1.75 Million ILS | -53.29% |
| 2019 Q3 | 18.14 Million ILS | -75.6% |
| 2018 Q3 | 3.09 Million ILS | -15.74% |
| 2018 Q1 | 2.23 Million ILS | 105.05% |
| 2018 FY | 12.76 Million ILS | -70.62% |
| 2018 Q4 | 3.76 Million ILS | 21.72% |
| 2018 Q2 | 3.67 Million ILS | 64.3% |
| 2017 Q4 | 1.09 Million ILS | -96.12% |
| 2017 Q2 | 4.95 Million ILS | -47.14% |
| 2017 Q1 | 9.36 Million ILS | 86.91% |
| 2017 FY | 43.46 Million ILS | 79.72% |
| 2017 Q3 | 28.05 Million ILS | 466.81% |
| 2016 Q2 | 7.61 Million ILS | 112.29% |
| 2016 Q1 | 3.58 Million ILS | 34.09% |
| 2016 Q3 | 7.97 Million ILS | 4.67% |
| 2016 FY | 24.18 Million ILS | -4.86% |
| 2016 Q4 | 5.01 Million ILS | -37.15% |
| 2015 Q3 | 6.22 Million ILS | -12.22% |
| 2015 FY | 25.41 Million ILS | 6.35% |
| 2015 Q2 | 7.09 Million ILS | -24.7% |
| 2015 Q4 | 2.67 Million ILS | -57.04% |
| 2015 Q1 | 9.42 Million ILS | -58.05% |
| 2014 Q2 | 388 Thousand ILS | 1.84% |
| 2014 Q1 | 381 Thousand ILS | 139.62% |
| 2014 FY | 23.89 Million ILS | 592.32% |
| 2014 Q4 | 22.45 Million ILS | 3247.09% |
| 2014 Q3 | 671 Thousand ILS | 72.94% |
| 2013 Q2 | 2.41 Million ILS | 21.75% |
| 2013 Q3 | 250 Thousand ILS | -89.66% |
| 2013 FY | 3.45 Million ILS | -55.0% |
| 2013 Q4 | 159 Thousand ILS | -36.4% |
| 2013 Q1 | 1.98 Million ILS | -14.58% |
| 2012 Q3 | 2.25 Million ILS | 17.67% |
| 2012 Q4 | 2.32 Million ILS | 3.01% |
| 2012 FY | 7.67 Million ILS | -15.4% |
| 2012 Q1 | 1.17 Million ILS | 0.0% |
| 2012 Q2 | 1.91 Million ILS | 63.79% |
| 2011 FY | 9.06 Million ILS | 155.77% |
| 2010 FY | 3.54 Million ILS | -25.29% |
| 2009 FY | 4.74 Million ILS | 49.12% |
| 2008 FY | 3.18 Million ILS | 137.64% |
| 2007 FY | 1.33 Million ILS | -35.06% |
| 2006 FY | 2.06 Million ILS | 46.87% |
| 2005 FY | 1.4 Million ILS | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Matricelf Ltd | - ILA | -Infinity% |